Menu

Salk Gender-Discrimination Lawsuit to Go to Trial

A judge throws out several of researcher Beverly Emerson’s claims, but the case proceeds.

Sep 4, 2018
Shawna Williams

ABOVE: FLICKR, JASON TAELLIOUS

Molecular biologist Beverly Emerson’s case against the Salk Institute will go to trial this December, after a judge last week (August 30) threw out three of her claims but let one stand. Emerson, now a professor emerita at Salk, says she was for decades denied professional opportunities available to male faculty members at the institute.

“We are pleased with the court’s order and look forward to defending against the remaining claims,” Summer Wynn, an attorney representing the Salk, tells The San Diego Union-Tribune. Alreen Haeggquist, Emerson’s attorney, tells the publication that the decision was “a victory for Dr. Emerson, and a tremendous step forward for women scientists at Salk, as the court ruled that there is ample evidence to proceed to trial, and that the institute will be held accountable for decades of gender discrimination.”

See “Salk Faces Gender Discrimination Lawsuits

More than a year ago, Emerson joined two other Salk scientists, Vicki Lundblad and Katherine Jones, in suing the institute; Lundblad and Jones later settled. The trio, who together represented three-quarters of the institute’s female full professors, claimed that their labs received less funding than those of their colleagues and that their promotion rates were slower.

See “Salk Institute Settles Two Gender Discrimination Suits

In a statement last summer, Salk said Lundblad and Jones had “been treated generously by the institute, including relative to their male peers,” according to the Union-Tribune. “Each scientist’s lucrative compensation package is consistent with well-recognized metrics that have been applied to all Salk faculty in a nondiscriminatory manner.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.